Pharmaceutical stocks have lagged the broader market recently, with the Vanguard Health Care Fund ETF (NYSEMKT: VHT) trailing the S&P 500 by about 15% in the past year and 10% in the past five. And while a majority of big-pharma names (like Pfizer, Bristol Myers Squibb, and AbbVie) continue to underperform, Eli Lilly (NYSE: LLY) is an exception. One of the world’s largest pharmaceutical companies, Eli Lilly is poised to keep going higher, deploying its resources to tackle some of the biggest health challenges facing humanity today.
The company’s wide range of products treats conditions including cancer, diabetes, immune disorders, and more. As current blockbusters continue to set records and new treatments (including for Alzheimer’s disease) proceed in development, Eli Lilly is not a company healthcare investors will want to miss.